Literature DB >> 26818174

Response to rituximab in an anti-muscle-specific receptor tyrosine kinase- and anti-acetylcholine recepto-double-positive myasthenia gravis patient concomitant with follicular dendritic cell sarcoma.

Jianmeng Wang1, Xiujuan Wu, Hui Deng, Ye Liu, Hongping Liu, Xueli Fan, Kangding Liu, Jiang Wu, Hong-Liang Zhang.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2016        PMID： 26818174      PMCID： PMC5224420          DOI： 10.17712/nsj.2016.1.20150483

Source DB:  PubMed          Journal:  Neurosciences (Riyadh)        ISSN： 1319-6138            Impact factor:   0.906


× No keyword cloud information.
  4 in total

1.  Responsiveness to reduced dosage of rituximab in Chinese patients with neuromyelitis optica.

Authors:  Chun-Sheng Yang; Li Yang; Ting Li; Da-Qi Zhang; Wei-Na Jin; Min-Shu Li; Ning Su; Nannan Zhangning; Qiang Liu; Zong-Hong Shao; Chunshui Yu; Fu-Dong Shi
Journal:  Neurology       Date:  2013-07-24       Impact factor: 9.910

2.  AChR-myasthenia gravis switching to double-seropositive several years after the onset.

Authors:  Vasiliki Zouvelou; Paraskevi Zisimopoulou; Erasmia Psimenou; Eirini Matsigkou; Eleftherios Stamboulis; Socrates J Tzartos
Journal:  J Neuroimmunol       Date:  2013-12-22       Impact factor: 3.478

Review 3.  Autoimmune myasthenia gravis: emerging clinical and biological heterogeneity.

Authors:  Matthew N Meriggioli; Donald B Sanders
Journal:  Lancet Neurol       Date:  2009-05       Impact factor: 44.182

Review 4.  Dendritic cell neoplasms: an overview.

Authors:  Sebastien Kairouz; Jana Hashash; Wadih Kabbara; Wassim McHayleh; Imad A Tabbara
Journal:  Am J Hematol       Date:  2007-10       Impact factor: 10.047
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.